
Women4Oncology
@women4oncology
ID: 3335347053
https://www.facebook.com/womeninoncology?fref=ts 19-06-2015 19:31:52
27 Tweet
319 Followers
182 Following

Pivotal ph2 study in Nature Medicine showing that combining T-cell gene inflam signat and #TMB in NSCLC stratifies ORR to 1L Pembro plus either lenva/CTLA4/LAG3 combos. 50-60% ORR in “double-high” cohort. 👏Roy Herbst Daniel Tan Enriqueta Felip nature.com/articles/s4159…



#WCLC23 Solange Peters on 6-yrs outcome of CM-227: IPi+ nivo combo associated with deeper responses, deeper responses associate with better OS in both PD1+ and PDL1(-) strata and better HRQoL baseline associated with better outcomes OS: 22 vs 13% in PDL1+ 16 vs 5% in PDL1 neg



Terrific presentaion on the duration of immunotherapy from Marina Garassino… believers or not believers… until we have enough data please have a look to garassino’s algorithms for IO-duration IASLC ESMO - Eur. Oncology ASCO




New perspectives and creativity are what diversity brings to the workplace. ESMO supports the International Day of Women and Girls in Science. #WomenAndGirlsInScience #esmoW4O Women4Oncology W4O_Italy ΕΟΠΕ WinC - AlinC (Women in Cancer - All in Cancer)

International Women's Day 2024 theme is #InspireInclusion Women4Oncology celebrated our 10-year anniversary and awarded an inspirational woman leader in oncology, a strong advocate of inclusion and gender equity, the founder and first ESMO-W4O Chair Prof Solange Peters



Women Diagnosed with Early Breast Cancer Since 2000 Have About a Fifth Lower Rate of Distant Recurrence Than Those Diagnosed in the 1990s. Thanks ESMO - Eur. Oncology for highlighting our The Lancet commentary on the latest EBCTCG analysis of breast cancer outcomes. esmo.org/oncology-news/…







